Financing ·
eXoZymes Inc. completed a firm commitment underwritten offering of 592,270 units at $18.00 per unit, with each unit…
EXOZExozymes Inc.
eXoZymes Inc. completed a firm commitment underwritten offering of 592,270 units at $18.00 per unit, with each unit consisting of two shares of common stock and one warrant. On June 17, 2026, the underwriter MDB Capital exercised an over-allotment option to purchase 34,440 additional units. Including the over-allotment, the company generated approximately $5.95 million in gross proceeds. Net proceeds are intended to fund N-trans-caffeoyltyramine (NCT) development, research and development, and general working capital. eXoZymes Inc. is a biotechnology company focused on product development and commercialization.